Neuroprotective Agents: Therapeutic Applications and Global Markets

  • ID: 4559409
  • Report
  • Region: Global
  • 133 Pages
  • BCC Research
15 % OFF
until Dec 31st 2018
1 of 6
In 2015, Neurological Disorders Ranked as the Leading Cause of Lifelong Disabilities Among the Main Disease Groups and Were the Second Most Common Cause of Death

FEATURED COMPANIES

  • AB Science S.A.
  • Athersys Inc.
  • Boehringer Ingelheim
  • Covis Pharma
  • Glaxosmithkline Plc
  • Mitsubishi Pharma Corp.
  • MORE

Report Scope:

The scope of this report covers the global market for small molecule drugs, monoclonal antibodies, gene and cell therapies, and other biotechnology products that are approved or being developed for the treatment of neurological disorders.

Therapeutic indications are grouped into four categories: cerebrovascular diseases, neurodegenerative disorders, ophthalmic diseases and traumatic CNS injuries. Indication subcategories include stroke, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington’s disease, spinal muscular atrophy, epilepsy, glaucoma, age-related macular degeneration, optic neuropathies, diabetic retinopathy and traumatic brain and spinal cord injuries. The report does not cover the neuroprotective agents that are used for protecting the brain during risky neurosurgeries and other general operations.

Report Includes:

  • 39 tables
  • An overview of the global market for neuroprotective agents and their therapeutic applications
  • Analyses of global market trends, with data from 2016, 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Market breakdowns by indication, mechanism of action, and by region
  • Discussion of various neurodegenerative disorders
  • Profiles of key companies in the market, including Bayer Healthcare, Eisai Inc., Glaxosmithkline Plc, Merck Serono S.A., Novartis Ag and Teva Pharmaceutical Industries Ltd.

Membership Price:

Contact us for membership Pricing.

Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AB Science S.A.
  • Athersys Inc.
  • Boehringer Ingelheim
  • Covis Pharma
  • Glaxosmithkline Plc
  • Mitsubishi Pharma Corp.
  • MORE

1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related Reports

2 Summary and Highlights

3 Market and Technology Background

  • Neuroprotection
  • Why Are Neuroprotective Therapies Needed?
  • Neuroprotective Strategies
  • Cerebrovascular Disease
  • Stroke
  • Neuroprotection in Stroke
  • Neurodegenerative Disorders
  • Parkinson's Disease
  • Amyotrophic Lateral Sclerosis
  • Multiple Sclerosis
  • Alzheimer's Disease
  • Huntington's Disease
  • Spinal Muscular Atrophy
  • Epilepsy
  • Neuroprotection in Neurodegenerative Disorders
  • Ophthalmic Diseases
  • Glaucoma
  • Nonarteritic Anterior Ischemic Optic Neuropathy
  • Age-related Macular Degeneration
  • Diabetic Retinopathy
  • Neuroprotection in Ophthalmic Diseases
  • Traumatic CNS Injuries
  • Traumatic Brain Injury
  • Traumatic Spinal Cord Injuries
  • Neuroprotection in Traumatic CNS Injuries

4 Market Breakdown by Technology Type

  • Therapeutic Agents
  • Antisense Agents
  • Anti-amyloid Agents
  • Immune Response Modifiers
  • Antioxidants
  • Anti-angiogenic Agents
  • Anti-Parkinson's Agents
  • Anticonvulsants
  • Ocular Hypotensives
  • Thrombolytics
  • Blood Thinning Agents
  • Anti-dementia Agents
  • Other Neuroprotective Agents
  • Regenerative Medicine Products
  • Brainstorm Cell Therapeutics' Nurown as First ALS Cell Therapy in the U.S.
  • Neuronata-R to Expand to International ALS Markets
  • Multistem Fast-tracked for Ischemic Stroke
  • CEVA101 Advances in Traumatic Brain Injury Trials
  • Asterias Biotherapeutics Snatches RMAT for Spinal Cord Injuries
  • CTX0E03 Advances in PISCES II Trials for Stroke Disability

5 Market Breakdown by Therapeutic Indication

  • Neuroprotective Agents for Cerebrovascular Disease
  • Neuroprotective Agents for Neurodegenerative Disorders
  • Neuroprotective Agents for Ophthalmic Diseases
  • Neuroprotective Agents for Traumatic Central Nervous System Injuries

6 Market Breakdown by Region

7 Company Profiles

  • AB Science S.A.
  • Acucela Inc.
  • Aerie Pharmaceuticals Inc.
  • Allergan
  • Astrazeneca Plc
  • Athersys Inc.
  • Avexis Inc.
  • Bayer Healthcare
  • Biogen Inc.
  • Bristol-Myers Squibb Co.
  • Boehringer Ingelheim
  • Brainstorm Cell Therapeutics Inc.
  • Celgene Corp.
  • Corestem Inc.
  • Covis Pharma
  • Daiichi Sankyo Inc.
  • Eisai Inc.
  • Fortress Biotech Inc.
  • Genervon Biopharmaceuticals Llc
  • Glaxosmithkline Plc
  • Gw Pharmaceuticals Plc
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals Inc.
  • Medday Pharmaceuticals Sas
  • Merck Serono S.A.
  • Mitsubishi Pharma Corp.
  • Newron Pharmaceuticals Spa
  • Novartis Ag
  • Pfizer Inc.
  • Quark Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals Inc.
  • Reneuron Group Plc
  • Roche Holding Ag
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharma S.A.
  • Vertex Pharmaceuticals Inc.
  • VTV Therapeutics Inc.
  • Zogenix Inc.

List of Tables
Summary Table: Global Market for Neuroprotective Agents, by Region, Through 2022
Table 1: Global Market for Neuroprotective Agents, by Technology Type, Through 2022
Table 2: Global Market for Neuroprotective Agents, by Application, Through 2022
Table 3: Global Market for Therapeutic Agents, by Drug Class, Through 2022
Table 4: Global Market for Antisense Agents, Through 2022
Table 5: Global Market for Anti-Amyloid Agents, Through 2022
Table 6: Neuroprotective Interferons Available in Global Markets, by Brand
Table 7: Neuroprotective Monoclonal Antibodies Available in Global Markets, by Brand
Table 8: Key Immune Response Modifiers in Clinical Development
Table 9: Global Market for Immune Response Modifiers, Through 2022
Table 10: Key Antioxidants in Clinical Development
Table 11: Global Market for Antioxidants, Through 2022
Table 12: Key Anti-angiogenic Agents in Clinical Development
Table 13: Global Market for Anti-Angiogenic Agents, Through 2022
Table 14: Global Market for Anti-Parkinson’s Agents, Through 2022
Table 15: Key Anticonvulsants in Clinical Development
Table 16: Global Market for Anticonvulsants, Through 2022
Table 17: Global Market for Ocular Hypotensives, Through 2022
Table 18: Global Market for Thrombolytics, Through 2022
Table 19: Global Market for Blood Thinning Agents, Through 2022
Table 20: Global Market for Anti-Dementia Agents, Through 2022
Table 21: Key Neuroprotective Drug Candidates with Novel MoA in Clinical Development
Table 22: Global Market for Other Neuroprotective Agents, Through 2022
Table 23: Global Market for Regenerative Medicine Products, Through 2022
Table 24: Global Market Share for Key Players in Neuroprotection, 2017
Table 25: Global Market for Neuroprotective Agents, by Therapeutic Indication, Through 2022
Table 26: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, Through 2022
Table 27: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Type, Through 2022
Table 28: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Type, Through 2022
Table 29: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Type, Through 2022
Table 30: Global Market for Neuroprotective Agents, by Region, Through 2022
Table 31: North American Market for Neuroprotective Agents, by Indication, Through 2022
Table 32: European Market for Neuroprotective Agents, by Indication, Through 2022
Table 33: Asia-Pacific Market for Neuroprotective Agents, by Indication, Through 2022
Table 34: ROW Market for Neuroprotective Agents, by Indication, Through 2022
Table 35: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, by Region, Through 2022
Table 36: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Region, Through 2022
Table 37: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Region, Through 2022
Table 38: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Region, Through 2022

List of Figures
Summary Figure: Global Market for Neuroprotective Agents, by Region, 2016-2022
Figure 1: Global Market for Neuroprotective Agents, by Technology Type, 2016-2022
Figure 2: Global Market for Neuroprotective Agents, by Application, 2016-2022
Figure 3: Global Market for Therapeutic Agents, by Drug Class, 2016-2022
Figure 4: Global Market for Antisense Agents, 2016-2022
Figure 5: Global Market for Anti-Amyloid Agents, 2016-2022
Figure 6: Global Market for Immune Response Modifiers, 2016-2022
Figure 7: Global Market for Antioxidants, 2016-2022
Figure 8: Global Market for Anti-Angiogenic Agents, 2016-2022
Figure 9: Global Market for Anti-Parkinson’s Agents, 2016-2022
Figure 10: Global Market for Anticonvulsants, 2016-2022
Figure 11: Global Market for Ocular Hypotensives, 2016-2022
Figure 12: Global Market for Thrombolytics, 2016-2022
Figure 13: Global Market for Blood Thinning Agents, 2016-2022
Figure 14: Global Market for Anti-Dementia Agents, 2016-2022
Figure 15: Global Market for Other Neuroprotective Agents, 2016-2022
Figure 16: Global Market for Regenerative Medicine Products, 2016-2022
Figure 17: Global Market Share for Key Players in Neuroprotection, 2017
Figure 18: Global Market for Neuroprotective Agents, by Therapeutic Indication, 2016-2022
Figure 19: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, 2016-2022
Figure 20: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Type, 2017-2022
Figure 21: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Type, 2016-2022
Figure 22: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Type, 2016-2022
Figure 23: Global Market for Neuroprotective Agents, by Region, 2016-2022
Figure 24: North American Market for Neuroprotective Agents, by Indication, 2016-2022
Figure 25: European Market for Neuroprotective Agents, by Indication, 2016-2022
Figure 26: Asia-Pacific Market for Neuroprotective Agents, by Indication, 2016-2022
Figure 27: ROW Market for Neuroprotective Agents, by Indication, 2016-2022
Figure 28: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, by Region, 2016-2022
Figure 29: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Region, 2016-2022
Figure 30: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Region, 2016-2022
Figure 31: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Region, 2016-2022

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AB Science S.A.
  • Athersys Inc.
  • Boehringer Ingelheim
  • Covis Pharma
  • Glaxosmithkline Plc
  • Mitsubishi Pharma Corp.
  • MORE

According to the 2007 Global Burden of Disease report from the World Health Organization (WHO), more than 1 billion people worldwide suffered from neurological disorders, including stroke, Alzheimer’s disease, epilepsy, Parkinson’s disease (PD), brain injuries, and glaucoma and other eye disorders. Nearly 7 million people died from these diseases. According to the report, one in six people is stricken by a neurological disorder every year, many of them becoming seriously disabled.

In 2015, neurological disorders ranked as the leading cause of lifelong disabilities among the main disease groups and were the second most common cause of death. Stroke is the leading neurological disorder and it affects more than 15 million people every year worldwide, killing 5 million people and leaving an equal number of people with debilitating disabilities.

In 2015, AD affected more than 46 million people, and it was the second leading cause of death, after stroke. Neurodegenerative disorders such as AD, PD, multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) ranked in the 10 most fatal incurable diseases.

As life spans increase, most of the neurological disorders are becoming more prevalent. Common diseases of advanced age such as glaucoma, AD-associated dementia, age-related macular degeneration (AMD), diabetic retinopathy and PD affect nearly one-fourth of adults over 60.

In the U.S., 1.5 million people suffer from a traumatic central nervous system (CNS) injury each year. This number consists primarily of young adults and the elderly, due to reasons such as accidents, falls, sports- and work-related injuries, combat and self-harm. One-third of injury-related deaths in the U.S. are caused by traumatic brain injuries, which also lead to serious physical disabilities, cognitive disorders and neurodegenerative diseases.

Treating neurological disorders has proved to be greatly challenging. In addition to mostly insufficient clinical research in many neurological disorders, therapeutic limitations are due to a natural protective seal around the brain called the blood-brain barrier, which makes it extremely difficult to effectively diffuse a drug compound into the brain.

Neuroprotection is an approach to the treatment of neurological disorders through the use of therapies that are developed by learning from the brain’s own tools to protect nerve cells from damage, degeneration and death. The human brain, by large and small biological molecules and certain types of cells, can promote growth, survival and differentiation to adapt to sudden changes, trauma and disease. Neuroprotective agents in global markets and clinical pipelines include small molecule drugs, therapeutic monoclonal antibodies, gene therapies, cell therapies and other agents.

Note: Product cover images may vary from those shown
5 of 6
  • AB Science S.A.
  • Acucela Inc.
  • Aerie Pharmaceuticals Inc.
  • Allergan
  • Astrazeneca Plc
  • Athersys Inc.
  • Avexis Inc.
  • Bayer Healthcare
  • Biogen Inc.
  • Boehringer Ingelheim
  • Brainstorm Cell Therapeutics Inc.
  • Bristol-Myers Squibb Co.
  • Celgene Corp.
  • Corestem Inc.
  • Covis Pharma
  • Daiichi Sankyo Inc.
  • Eisai Inc.
  • Fortress Biotech Inc.
  • Genervon Biopharmaceuticals Llc
  • Glaxosmithkline Plc
  • GW Pharmaceuticals Plc
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals Inc.
  • Medday Pharmaceuticals Sas
  • Merck Serono S.A.
  • Mitsubishi Pharma Corp.
  • Newron Pharmaceuticals Spa
  • Novartis Ag
  • Pfizer Inc.
  • Quark Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals Inc.
  • Reneuron Group Plc
  • Roche Holding Ag
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharma S.A.
  • Vertex Pharmaceuticals Inc.
  • VTV Therapeutics Inc.
  • Zogenix Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll